期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

慢性乙型肝炎患者核苷(酸)类药物长期抗病毒治疗的安全性 被引量：3

Safety of Long-Term Anti-Viral Treatment with Nucleos( t ) ide Analogues for Patients with Chronic Hepatitis B
下载PDF
导出
摘要 大多数接受核苷(酸)(nucleos(t)ide analogues,NAs)类药物治疗的慢性乙型肝炎(chronic hepatitis B,CHB)患者需要长期治疗,部分患者甚至需要终身治疗,而且患者个体间通常存在明显的差异,因此在临床应用过程中需要密切监测NAs类药物长期治疗的安全性。本文旨在对NAs类药物长期抗病毒治疗的安全性数据进行回顾总结,加强广大临床医师对相关安全性问题的认识,并为临床实践提供指导。 Most chronic hepatitis B（ CHB） patients need long-term treatment with nucleos（ t） ide analogues（ NAs）,whereas part of them even need life-long treatment. However,due to heterogeneity of human beings,it is great important to monitor the longterm safety of NAs in the management of patients with chronic hepatitis B in clinical practice. This article aimed to review the safety data of long-term anti-viral treatment with NAs with the expectation to enhance the awareness of clinicians to these issues and support clinical practice.
作者 陈小苹 彭劼 谢奇峰 许敏 叶晓光
机构地区 广东省药学会慢性乙型肝炎长期抗病毒治疗安全性讨论专家组
出处 《今日药学》 CAS 2015年第3期148-155,共8页 Pharmacy Today
关键词 慢性乙型肝炎 核苷(酸)类药物 安全性 chronic hepatitis B nucleos（t） ide analogues safety
分类号 R512.62 [医药卫生—内科学]
  • 相关文献

参考文献6

二级参考文献51

共引文献93

同被引文献35

  • 1Zhang CX,Hu J,Hu KW,et al.Noninvasiveanalysis of portal pressure by contrast-enhancedsonography in patients with cirrhosis[J].JUltrasound Med,2011,30(2):205-211.
  • 2European Association for the study of the Liver.EASL clinical practice guidelines:management ofchronic hepatitis B[J].J Hepatol,2009,50(2):227-242.
  • 3Grnbaek H,Sandahl TD,Mortensen C,et al.S o l u b l e C D 1 6 3 , a m a r k e r o f K u p f f e r c e l lactivation,is related to portal hypertension inpatients with liver cirrhosis[J].Aliment PharmacolTher,2012,36(2):173-180.
  • 4Delviks-Frankenberry KA,Nikolenko GN,PathakVK.The"Connection"Between HIV DrugResistance and RNase H[J].Viruses,2010,2(7):1476-1503.
  • 5Kim MY,Suk KT,Baik SK,et al.Hepatic veinarrival time as assessed by contrast-enhancedultrasonography is useful for the assessment ofportal hypertension in compensated cirrhosis[J].Hepatology,2012,56(3):1053-1062.
  • 6Ari-n KK,Venkatraj M,Míchiels J,et al.D e v e l o p m e n t o f t r i a z i n e n o n - n u c l e o s i d ereverse transcriptase inhibitors for microbicidalapplications[J].Retrovirology,2011,8(Suppl 2):441-452.
  • 7Van Rompay KK, Trott KA, Jayashankar K,et al.Prolonged tenofovir treatment of macaquesinfected with K65R reverse transcriptase mutantsof SIV results in the development of antiviralimmune responses that control virus replicationafter drug withdrawal[J].Retrovirology,2012,9:57.
  • 8L a b i b M , S h i p m a n P O , M a r t i - S, e t a l . Ab i o o r g a n o m e t a l l i c a p p r o a c h f o r r a p i delectrochemical analysis of human immunodeficiencyvirus type-1 reverse transcriptase inserum[J].Electrochimica Acta,2011,56(14):3416-3420.
  • 9V a n de r Bor gh t K,Van Cr a e n e n - b r oe c kE,Lecocq P,et al.Cross-validated stepwiseregression for identification of novel nonnucleosidereverse transcriptase inhibitorr e s i s t a n c e a s s o c i a t e d m u t a t i o n s [J] . BMCBioinformatics,2011,12:386.
  • 10Pol S,Lampertico P.First-line treatment of chronichepatitis B with entecavir or tenofovir in'reallife'settings:from clinical trials to clinicalpractice[J].J Viral Hepat,2012,19(6):377-386.

引证文献3

今日药学
2015年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部